Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with the British Association of Dermatologists on the suitability of Severity of Alopecia Tool scores to determine treatment for alopecia.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
There have been no discussions between the current health ministers in England and the British Association of Dermatologists (BAD) on the suitability of the Severity of Alopecia Tool’s (SALT) scores to determine treatment for alopecia areata.
However, we understand that BAD has acknowledged that whilst SALT is a helpful tool, it does not fully capture the overall impact of alopecia areata on an individual's life, including psychological distress and hair loss in other areas. Its 2024 living guideline for managing people with alopecia areata considers factors beyond scalp hair loss, such as other body hair loss, to assess the severity of alopecia areata.
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many health boards have used Ritlecitinib to treat alopecia in the last 12 months.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The NHS Business Services Authority and NHS England only hold prescribing data for ritlecitinib in England. As health is a devolved issue, information relating to the use of ritlecitinib by Scottish health boards would be held by the Scottish health authorities.
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will conduct an audit of health infrastructure classified as critically important to national interests to identify whether they contain Chinese-made components.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom will not compromise on economic security and will continue to prioritise national security and resilience. We will continue to cooperate with China on trade and investment, recognising that there will also be areas where we need to challenge non-market policies and protect sensitive sectors of the economy. We will continue to support UK business to engage with the second largest economy in the world, while being clear-eyed to any risks, and ensuring security and resilience. The national technical authorities, namely the National Protective Security Authority and the National Cyber Security Centre, provide advice to critical national infrastructure, including in the health sector, on best practice for security and resilience. The Department does not comment on specific policy matters related to its critical national infrastructure.
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Research has undertaken research on the potential impact of psychedelic medication on the treatment of severe mental health conditions.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is supporting psilocybin research via the NIHR King’s Clinical Research Facility and the NIHR Maudsley Biomedical Research Centre, where researchers are developing and evaluating the efficacy and safety of psilocybin therapy for use in the National Health Service and other healthcare settings. The NIHR continues to welcome funding applications for research into any aspect of human health, including research on the potential impact of psychedelic substances for the treatment of severe mental health conditions.
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding the Government has provided for endometriosis research in each of the last five years; and what proportion of Government-funded medicinal research that accounts for.
Answered by Andrew Gwynne
The Department funds research through the National Institute for Health and Care Research (NIHR). The following table shows how much funding the NIHR has awarded for endometriosis research, as well as that spend as a percentage of total urogynaecology research spend, for each year from 2019/20 to 2023/24:
Financial year | Spend | Proportion of total urogynaecology spend |
2019/20 | £493,945 | 8.9% |
2020/21 | £554,151 | 10.5% |
2021/22 | £973,089 | 16.8% |
2022/23 | £1,360,614 | 24.9% |
2023/24 | £1,325,329 | 21.9% |
This information reflects in-year payments to 10 research awards that were active during this time period. It does not reflect the total award value. The total award value for these awards, across their full duration, is £7,714,953.
In addition, between 2019/20 and 2023/24, there were 18 awards with relevance to endometriosis active on UK Research and Innovation’s (UKRI) portfolio. These awards had a total value of £8.43 million. The following table shows the in-year expenditure for this research, for each year from 2019/20 to 2023/24:
Financial year | In year spend | Percentage of spend versus UKRI research base outturn |
2019/20 | £585,662 | <1% |
2020/21 | £683,812 | <1% |
2021/22 | £1,017,417 | <1% |
2022/23 | £1,264,127 | <1% |
2023/24 | £1,589,230 | <1% |
The remaining spend is slated for future financial years.
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what training is provided to NHS staff to highlight the differences in symptoms of a heart attack between men and women.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Guidance for National Health Service staff is available through the British Heart Foundation, and specific learning sessions are available to support training, with further information on both available, respectively, at the following two links:
https://www.chsselearning.org.uk/hearte/15-womens-health/
NHS England has been cognisant of gender differences when running public campaigns, and as such has ensured clear messaging on atypical symptoms in women. This has been represented through sharing patient stories within campaign material, highlighting the differences in gender symptoms. Further information on NHS England’s public campaign is available at the following link:
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of differences in approved medicines on (a) men and (b) women.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency is responsible for approving medicines in the United Kingdom before they are made available to the wider public. This involves a rigorous assessment using data from clinical trials to assess safety and efficacy.
If data suggests that a medicine may have a different effect on men and women, this is considered within the assessment process. Every medicine is assessed on a case-by-case basis, as several factors may impact the performance of a specific product.
Post authorisation, where there is identified or potential differences between men and women in safety or effectiveness, this can be monitored in the risk management plan. The agency keeps the safety and effectiveness of all medicines under continual monitoring in all populations. Should any differences in outcomes between men and women be identified, the agency will take appropriate regulatory action.
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what testing requirements are in place in the approval process to identify the different impacts of medicines on men and women.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
As part of the approval process for new drugs, the impact of sex, on men versus women, is assessed on pharmacokinetics, or exposure, pharmacodynamics, and overall efficacy and safety. The data is assessed in terms of whether any dose adjustments are warranted. Data in pregnant and breast-feeding women is also required where relevant.
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many medicinal approvals used female physiology as a baseline for testing in each of the last five years.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency does not capture this information in a searchable format, however this information would be available in Public Assessment Reports and summaries of product characteristics, where relevant. These documents are available at the following link:
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when NHS England last reviewed guidance for hyperemesis gravidarum; and whether that review was shared with (a) the Scottish Government and (b) NHS Scotland.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We recognise the challenges including the emotional and physical impacts that hyperemesis gravidarum can have on pregnant women and their families. Appropriate and evidence-based guidance is crucial.
NHS England regularly reviews all health guidance, including relevant guidance on managing hyperemesis gravidarum. In its guidance on antenatal care, the National Institute for Health and Care Excellence refers to the Royal College of Obstetricians and Gynaecologists’ guidance on hyperemesis gravidarum which is also available for patients and staff to consider.
We continue to work closely with counterparts in the devolved nations, including the Scottish Government and NHS Scotland.